{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:23:23Z","timestamp":1707524603906},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,31]]},"DOI":"10.7759\/cureus.23718","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T06:56:05Z","timestamp":1648796165000},"source":"Crossref","is-referenced-by-count":0,"title":["Acute Multiple In-Stent Thromboses in a Patient With Clopidogrel-Fluconazole Interaction"],"prefix":"10.7759","author":[{"given":"Antoine","family":"El Khoury","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zela Maria","family":"Butchakdjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Lagha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Semaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maroun","family":"Soueidy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03999.x","article-title":"Anti-platelet therapy: ADP receptor antagonists","volume":"72","author":"Wijeyeratne YD","year":"2011","unstructured":"Wijeyeratne YD, Heptinstall S. Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol. 2011, 72:647-57. 10.1111\/j.1365-2125.2011.03999.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2153-7","article-title":"Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1\/2 inhibitor, in healthy subjects: results from two clinical trials","volume":"73","author":"Dymond AW","year":"2017","unstructured":"Dymond AW, So K, Martin P, et al.. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1\/2 inhibitor, in healthy subjects: results from two clinical trials. Eur J Clin Pharmacol. 2017, 73:175-84. 10.1007\/s00228-016-2153-7","journal-title":"Eur J Clin Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S83293","article-title":"Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions","volume":"11","author":"Saab YB","year":"2015","unstructured":"Saab YB, Zeenny R, Ramadan WH. Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions. Ther Clin Risk Manag. 2015, 11:1421-7. 10.2147\/TCRM.S83293","journal-title":"Ther Clin Risk Manag"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/09537109876799","article-title":"Clopidogrel: a review of its mechanism of action","volume":"9","author":"Savi P","year":"1998","unstructured":"Savi P, Nurden P, Nurden AT, Levy-Toledano S, Herbert JM. Clopidogrel: a review of its mechanism of action. Platelets. 1998, 9:251-5. 10.1080\/09537109876799","journal-title":"Platelets"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03949.x","article-title":"Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?","volume":"72","author":"Ma TK","year":"2011","unstructured":"Ma TK, Lam YY, Tan VP, Yan BP. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?. Br J Clin Pharmacol. 2011, 72:697-706. 10.1111\/j.1365-2125.2011.03949.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1477","article-title":"Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety","volume":"34","author":"Dobesh PP","year":"2014","unstructured":"Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2014, 34:1077-90. 10.1002\/phar.1477","journal-title":"Pharmacotherapy"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1076029609355589","article-title":"Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist","volume":"16","author":"Mousa SA","year":"2010","unstructured":"Mousa SA, Jeske WP, Fareed J. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist. Clin Appl Thromb Hemost. 2010, 16:170-6. 10.1177\/1076029609355589","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet JP","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, et al.. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021, 42:1289-367. 10.1093\/eurheartj\/ehaa575","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M051","article-title":"Drug-drug interaction between clopidogrel and the proton pump inhibitors","volume":"43","author":"Norgard NB","year":"2009","unstructured":"Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother. 2009, 43:1266-74. 10.1345\/aph.1M051","journal-title":"Ann Pharmacother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.594069","article-title":"Personalized approaches to clopidogrel therapy: are we there yet?","volume":"41","author":"Anderson CD","year":"2010","unstructured":"Anderson CD, Biffi A, Greenberg SM, Rosand J. Personalized approaches to clopidogrel therapy: are we there yet?. Stroke. 2010, 41:2997-3002. 10.1161\/STROKEAHA.110.594069","journal-title":"Stroke"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M237","article-title":"Echinocandins: the newest class of antifungals","volume":"43","author":"Sucher AJ","year":"2009","unstructured":"Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009, 43:1647-57. 10.1345\/aph.1M237","journal-title":"Ann Pharmacother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-13-18","article-title":"The polyene antifungals, amphotericin B and nystatin, cause cell death in Saccharomyces cerevisiae by a distinct mechanism to amphibian-derived antimicrobial peptides","volume":"13","author":"Serhan G","year":"2014","unstructured":"Serhan G, Stack CM, Perrone GG, Morton CO. The polyene antifungals, amphotericin B and nystatin, cause cell death in Saccharomyces cerevisiae by a distinct mechanism to amphibian-derived antimicrobial peptides. Ann Clin Microbiol Antimicrob. 2014, 13:18. 10.1186\/1476-0711-13-18","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(90)70288-s","article-title":"Pharmacology of the allylamines","volume":"23","author":"Birnbaum JE","year":"1990","unstructured":"Birnbaum JE. Pharmacology of the allylamines. J Am Acad Dermatol. 1990, 23:782-5. 10.1016\/0190-9622(90)70288-s","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S80437","article-title":"Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy","volume":"11","author":"Wang ZY","year":"2015","unstructured":"Wang ZY, Chen M, Zhu LL, Yu LS, Zeng S, Xiang MX, Zhou Q. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 2015, 11:449-67. 10.2147\/TCRM.S80437","journal-title":"Ther Clin Risk Manag"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-0967-z","article-title":"The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study","volume":"128","author":"Macaskill EJ","year":"2011","unstructured":"Macaskill EJ, Bartlett JM, Sabine VS, et al.. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study. Breast Cancer Res Treat. 2011, 128:725-34. 10.1007\/s10549-010-0967-z","journal-title":"Breast Cancer Res Treat"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/90938-acute-multiple-in-stent-thromboses-in-a-patient-with-clopidogrel-fluconazole-interaction","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:11Z","timestamp":1707507371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/90938-acute-multiple-in-stent-thromboses-in-a-patient-with-clopidogrel-fluconazole-interaction"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.23718","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,31]]}}}